Kane Biotech Income Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	0.57	2.08	0.15	0.16	1.61	1.34
Revenue Growth (YoY)	-71.44%	1296.75%	-4.95%	-90.25%	19.84%	-20.78%
Cost of Revenue	0.67	1.21	0.04	0.04	1.04	0.81
Gross Profit	-0.1	0.87	0.11	0.11	0.57	0.53
Selling, General & Admin	1.79	3.08	2.41	2.53	4.07	3.43
Research & Development	0.91	1.51	1.05	1.04	1.31	1.29
Operating Expenses	2.7	4.59	3.46	3.57	5.39	4.71
Operating Income	-2.8	-3.72	-3.35	-3.46	-4.82	-4.18
Interest Expense	-0.29	-0.55	-1.22	-0.82	-0.42	-0.12
Interest & Investment Income	0.02	0	0.01	0.02	0.12	0.04
Currency Exchange Gain (Loss)	-0.01	-0.01	0	-0.02	0	0
EBT Excluding Unusual Items	-3.07	-4.27	-4.56	-4.28	-5.11	-4.27
Asset Writedown	-0.21	-0.21	-0.01	-	-0.07	-0.04
Other Unusual Items	0.02	-	0	0.25	0.32	0.46
Pretax Income	-3.26	-4.47	-4.56	-4.02	-4.85	-3.85
Income Tax Expense	-1.31	-1.31	-	-	-	-
Earnings From Continuing Operations	-1.95	-3.16	-4.56	-4.02	-4.85	-3.85
Earnings From Discontinued Operations	-1.31	9.26	-0.47	0.13	-	-
Net Income to Company	-3.26	6.1	-5.03	-3.89	-4.85	-3.85
Minority Interest in Earnings	-	-	-	-	0.25	0.13
Net Income	-3.26	6.1	-5.03	-3.89	-4.6	-3.72
Net Income to Common	-3.26	6.1	-5.03	-3.89	-4.6	-3.72
Shares Outstanding (Basic)	189	134	127	121	113	109
Shares Outstanding (Diluted)	189	155	127	121	113	109
Shares Change (YoY)	34.53%	22.23%	5.32%	7.20%	3.67%	31.97%
EPS (Basic)	-0.02	0.05	-0.04	-0.03	-0.04	-0.03
EPS (Diluted)	-0.02	0.05	-0.04	-0.03	-0.04	-0.03
Free Cash Flow	-3	-4.14	-2.09	-3.05	-2.48	-3.97
Free Cash Flow Per Share	-0.02	-0.03	-0.02	-0.03	-0.02	-0.04
Gross Margin	-16.60%	41.91%	73.48%	71.48%	35.36%	39.27%
Operating Margin	-486.26%	-178.66%	-2248.93%	-2206.05%	-299.63%	-311.93%
Profit Margin	-566.62%	293.05%	-3379.05%	-2481.86%	-286.39%	-277.04%
Free Cash Flow Margin	-522.57%	-198.77%	-1403.79%	-1947.70%	-153.99%	-295.64%
EBITDA	-2.72	-3.62	-3.23	-3.3	-4.73	-4.12
EBITDA Margin	-	-174.05%	-	-	-294.36%	-
D&A For EBITDA	0.07	0.1	0.12	0.16	0.08	0.07
EBIT	-2.8	-3.72	-3.35	-3.46	-4.82	-4.18
EBIT Margin	-	-178.66%	-	-	-299.63%	-
Revenue as Reported	2.08	2.08	0.15	0.16	1.61	1.34

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.